Immunogenicity of an adalimumab biosimilar, FKB327, and its reference product in patients with rheumatoid arthritis

AIM: This study, FKB327‐003, is a phase 3, open‐label extension (OLE) study comparing the long‐term immunogenicity of an adalimumab biosimilar, FKB327 (F), with the reference product (RP). METHODS: In the OLE, patients completing 24 weeks of an initial randomized, double‐blind (DB) study (Period 1)...

Descripción completa

Detalles Bibliográficos
Autores principales: Alten, Rieke, Markland, Colin, Boyce, Malcolm, Kawakami, Kazuki, Muniz, Rafael, Genovese, Mark C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754138/
https://www.ncbi.nlm.nih.gov/pubmed/32852139
http://dx.doi.org/10.1111/1756-185X.13951

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754138/
https://www.ncbi.nlm.nih.gov/pubmed/32852139
http://dx.doi.org/10.1111/1756-185X.13951

Ejemplares similares